NeoRx
Executive Summary
Paul Abrams, MD/JD, named president and CEO, replacing Robert Abbott, who will focus his efforts on "corporate partnering." Abbott retains seat on NeoRx board.
You may also be interested in...
UCB And Microsoft Expand AI Tie-Up Beyond COVID-19
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Coherus Aiming For More Than 10% Slice Of US Adalimumab Market
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: